» Articles » PMID: 1722791

The Pathophysiology of Benign Prostatic Hyperplasia

Overview
Journal J Androl
Date 1991 Nov 1
PMID 1722791
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Although benign prostatic hyperplasia (BPH) is one of the most common disease processes affecting the aging male, surprisingly little is known about its pathophysiology. Cause-and-effect relationships have not been established, despite intense research efforts in the last four or five decades aimed at elucidating the underlying etiology of prostatic growth in older men. Previously held notions that the clinical symptoms of BPH (prostatism) are due simply to a mass-related increase in urethral resistance are too simplistic. It is now clear that a significant portion of the symptoms are due to obstruction-induced detrusor dysfunction. Moreover, obstruction may induce a variety of neural alterations in the bladder and prostate that contribute to symptomatology. Undoubtedly, the constellation of cellular pathologies that give rise to the symptoms of BPH will be far more complex than we currently realize. Only by unraveling these complexities, however, will we be able successfully to design alternative strategies to treat, and possibly prevent BPH.

Citing Articles

Extract Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating Androgen Levels, Cell Proliferation, and Apoptosis.

Kumbukgahadeniya P, Baek E, Hong E, Song J, Kwak Y, Jang M Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598426 PMC: 11597678. DOI: 10.3390/ph17111516.


Current Understanding of Androgen Signaling in Prostatitis and its Treatment: A Review.

Cabeza M Curr Med Chem. 2024; 31(27):4249-4266.

PMID: 38243983 DOI: 10.2174/0109298673279207231228070533.


Role of prostate stem cells and treatment strategies in benign prostate hyperplasia.

Gangavarapu K, Jowdy P, Foster B, Huss W Am J Clin Exp Urol. 2022; 10(3):154-169.

PMID: 35874288 PMC: 9301063.


Zinc Deficiency in Men Over 50 and Its Implications in Prostate Disorders.

Sauer A, Vela H, Vela G, Stark P, Barrera-Juarez E, Grabrucker A Front Oncol. 2020; 10:1293.

PMID: 32850402 PMC: 7424038. DOI: 10.3389/fonc.2020.01293.


Can Botulinum Toxin A Still Have a Role in Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Through Inhibition of Chronic Prostatic Inflammation?.

Chiang B, Kuo H, Liao C Toxins (Basel). 2019; 11(9).

PMID: 31546892 PMC: 6784075. DOI: 10.3390/toxins11090547.